Woodline Partners LP Cuts Position in Immatics (NASDAQ:IMTX)

Woodline Partners LP lessened its stake in shares of Immatics (NASDAQ:IMTX - Free Report) by 18.7% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 2,034,224 shares of the company's stock after selling 467,738 shares during the quarter. Woodline Partners LP owned approximately 1.70% of Immatics worth $14,463,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. Bank of America Corp DE lifted its holdings in shares of Immatics by 166.0% during the fourth quarter. Bank of America Corp DE now owns 3,575 shares of the company's stock worth $25,000 after purchasing an additional 2,231 shares during the period. Virtus ETF Advisers LLC raised its holdings in shares of Immatics by 34.8% in the 4th quarter. Virtus ETF Advisers LLC now owns 9,594 shares of the company's stock worth $68,000 after acquiring an additional 2,479 shares during the last quarter. Guggenheim Capital LLC acquired a new stake in shares of Immatics in the 4th quarter worth about $101,000. Forefront Analytics LLC increased its stake in Immatics by 42.3% in the 4th quarter. Forefront Analytics LLC now owns 15,911 shares of the company's stock valued at $113,000 after buying an additional 4,731 shares during the last quarter. Finally, Graham Capital Management L.P. purchased a new stake in shares of Immatics during the 4th quarter worth approximately $130,000. Institutional investors own 64.41% of the company's stock.

Immatics Price Performance

Immatics stock traded up $0.03 during mid-day trading on Tuesday, hitting $5.14. The company's stock had a trading volume of 53,673 shares, compared to its average volume of 650,758. The stock has a market cap of $624.77 million, a price-to-earnings ratio of -7.77 and a beta of 0.87. The business has a 50 day moving average price of $4.52 and a 200-day moving average price of $5.65. Immatics has a 12 month low of $3.30 and a 12 month high of $13.77.

Immatics (NASDAQ:IMTX - Get Free Report) last issued its quarterly earnings data on Tuesday, May 13th. The company reported ($0.35) EPS for the quarter, beating the consensus estimate of ($0.39) by $0.04. Immatics had a negative net margin of 47.94% and a negative return on equity of 15.90%. The firm had revenue of $20.12 million during the quarter, compared to the consensus estimate of $14.92 million. On average, equities research analysts expect that Immatics will post -0.72 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms recently weighed in on IMTX. Cantor Fitzgerald reiterated an "overweight" rating on shares of Immatics in a research note on Tuesday, April 1st. Wall Street Zen downgraded shares of Immatics from a "hold" rating to a "strong sell" rating in a report on Thursday, May 22nd. One investment analyst has rated the stock with a sell rating, three have issued a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, Immatics presently has a consensus rating of "Moderate Buy" and a consensus target price of $17.00.

Immatics Company Profile

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.